Molecular structure of Polyglutamine Aggregation Inhibitor III, C2-8, CAS Number: 300670-16-0
Polyglutamine Aggregation Inhibitor III, C2-8 (CAS 300670-16-0)
Alternate Names:
N-(4-bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl]-benzamide
Application:
Polyglutamine Aggregation Inhibitor III, C2-8 is an amidosulfonamide inhibitor of polyglutamine aggregation
CAS Number:
300670-16-0
Purity:
≥95%
Molecular Weight:
510.20
Molecular Formula:
C19H14Br2N2O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Polyglutamine Aggregation Inhibitor III, C2-8 is a cell-permeable amidosulfonamide compound that potently and effectively inhibits polyglutamine (polyQ) aggregation in Huntington′s disease (HD) CA1 neuronal hippocampal sections at a range of 0.1 muM - 10 muM, and in PC12 Htt-103Q-EGFP cells with an IC50 of 50 nM. In addition, Polyglutamine Aggregation Inhibitor III, C2-8 alleviates progressive neurodegeneration in Drosophila expressing Httex1 93QP in a dose-dependent manner. Polyglutamine Aggregation Inhibitor III, C2-8 is a synthetic compound classified as a sulfonamide.
Polyglutamine Aggregation Inhibitor III, C2-8 (CAS 300670-16-0) References
- New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions. | Bodner, RA., et al. 2006. Cell Cycle. 5: 1477-80. PMID: 16861893
- Conformational variability of the intracellular domain of Drosophila Notch and its interaction with Suppressor of Hairless. | Kelly, DF., et al. 2007. Proc Natl Acad Sci U S A. 104: 9591-6. PMID: 17535912
- A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. | Chopra, V., et al. 2007. Proc Natl Acad Sci U S A. 104: 16685-9. PMID: 17925440
- Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. | Truant, R., et al. 2008. FEBS J. 275: 4252-62. PMID: 18637947
- A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. | Taylor, DM., et al. 2011. ACS Chem Biol. 6: 540-6. PMID: 21370928
- An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease. | Wang, N., et al. 2013. J Huntingtons Dis. 2: 443-51. PMID: 25062731
- Therapeutic Advances for Huntington's Disease. | Kumar, A., et al. 2020. Brain Sci. 10: PMID: 31940909
Inhibitor of:
caspase-2, and Huntingtin.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Polyglutamine Aggregation Inhibitor III, C2-8, 1 mg | sc-202766A | 1 mg | $47.00 | |||
Polyglutamine Aggregation Inhibitor III, C2-8, 5 mg | sc-202766B | 5 mg | $179.00 | |||
Polyglutamine Aggregation Inhibitor III, C2-8, 10 mg | sc-202766 | 10 mg | $312.00 | |||
Polyglutamine Aggregation Inhibitor III, C2-8, 25 mg | sc-202766C | 25 mg | $709.00 |